Clinical Trials
5 trialsNCT07553767 2026-04-28
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
Ningbo No.2 Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT05671315 2023-05-25
A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients
Ruijin Hospital
Phase NA Unknown
NCT02982720 2022-02-16
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00759109 2017-04-07
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00055809 2013-01-23
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Completed